Touchlight wins prestigious Lloyds Bank National Business Award
Hampton, UK – 11 November 2020 – Touchlight was announced the winner of The LDC Growth Through Innovation Award at the prestigious 2020 Lloyds Bank National Business Awards, which took place during an online ceremony on 10 November.
Commenting on the awards, Jonny Ohlson, Founder and Executive Chairman of Touchlight, said:
“It is a privilege to receive this award on behalf of the Touchlight team. After a transformative year for the Company, we’re delighted to have won the LDC Growth Through Innovation Award.
“Vaccines have been in the limelight this year, and we are grateful to Lloyds Bank National Business Awards for recognizing our commitment and our innovative dbDNA technology in helping develop and deliver vital vaccines across the globe.”
The Judges of the LDC Growth Through Innovation Award commented on Touchlight:
“Super innovative, pioneering, disruptor – a team of game changers.”
Sarah Austin, Awards Director, added:
“2020 has been a challenging but inspiring year; a year where we’ve witnessed just how innovative and adaptive the UK business community can be, whether that means helping employees adjust to new ways of working or shifting production towards masks, ventilators and handwash. This year’s winners are testament to the creativity, agility and resilience that sets British business apart.”
About the National Business Awards
Open to organisations of all sizes from all sectors across the UK, the Lloyds Bank National Business Awards programme is the UK’s most prestigious independent business recognition platform with particular emphasis on excellence, innovation and ethical business. Now in their 19th year, the Lloyds Bank National Business Awards connect the nation’s professionals through this annual awards ceremony, year-round thought leadership and round table events. Visit www.nationalbusinessawards.co.uk for further information or follow us on Twitter @businessawards.
The Lloyds Bank National Business Awards is organised by Informa Markets, a division of Informa plc – a leading B2B information services group and the largest B2B Events organiser in the world.
- ENDS -
Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as “doggybone” or dbDNA™.
dbDNA™ is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.
Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.
Issued for and on behalf of Touchlight by Instinctif Partners.
For more information please contact:
|Jonny Ohlson, CEO||Tim Watson / Agnes Stephens /|
|Tommy Duncan, CBO||Katie Duffell|
|E: email@example.com||E: firstname.lastname@example.org|
|T: +44 20 8481 9200||T: +44 20 7457 2020|